Compugen Predictive Discovery Capabilities Presented by CTO at Bio-IT Conference and Expo 2009

TEL AVIV, Israel--(Business Wire)--
Speaking today at the Bio-IT Conference and Expo 2009 in Boston, MA, Compugen`s
chief technology officer, Dr. Yossi Cohen, presented an overview of the
company`s capabilities and recent achievements in computer based predictive
discovery of drug and diagnostic product candidates, emphasizing the power, cost
effectiveness and broad applicability of these proprietary methodologies.

In his presentation, titled "Predictive In-silico Science: Shifting the
Discovery Paradigm", Dr. Cohen provided examples of product candidate
discoveries and recent validation results from several of the Company`s ten
discovery platforms. These included product candidates from its GPCR ligands and
DAC blockers platforms - both designed for the discovery of novel therapeutic
peptide drug candidates but based on different predictive methodologies - and
candidates from a platform designed for the discovery of novel targets for
antibody therapeutics.

Dr. Cohen explained how each Compugen discovery platform incorporates in silico
prediction and selection components leading to multiple putative product
candidates. These candidates are then prioritized for experimental validation.

Dr. Cohen stated, "The development of an increasing number of discovery
platforms, each addressing a different field of drug, drug target or biomarker
discovery, and the subsequent discovery of attractive product candidates from
each, continues to be achieved at Compugen by a well experienced and focused
multidisciplinary team of scientists."

"This is possible," Dr. Cohen continued, "because of a substantial and growing
portfolio of underlying computational biology capabilities, a product of more
than a decade of research efforts focused on obtaining deeper predictive
understandings and the modeling of key biological phenomena. These proprietary
underlying capabilities both lead us to potential new areas for discovery and
are available to us whenever we begin work on a new platform. In fact, what we
often find is that a considerable portion of the components and understandings
necessary to build a new field-focused platform is already available to us when
we begin the project."

Dr. Cohen concluded by highlighting two important observations from Compugen`s
broad experience in the field of predictive discovery. First is the importance
of assessing in advance how amenable the underlying scientific question of
interest is to computational discovery approaches in general, and specifically
to Compugen`s growing portfolio of proprietary capabilities; and second, the
absolute necessity of supporting experimental data to confirm, validate and
expand the resulting predictive power.

About Compugen

Compugen (NASDAQ:CGEN) is a leading drug and diagnostic product candidate
discovery company. Unlike traditional high throughput trial and error
experimental based discovery, Compugen`s discovery efforts are based on
in-silico (by computer) prediction and selection utilizing a growing number of
field focused proprietary discovery platforms accurately modeling biological
processes at the molecular level. The resulting product candidates are then
validated through in vitro and in vivo experimental studies and out-licensed for
further development and commercialization under various forms of revenue sharing
agreements. Compugen`s current collaborations include Biosite, Medarex, Inc.,
Merck & Co., Inc., Ortho-Clinical Diagnostics (a Johnson & Johnson company),
Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries.
In 2002, Compugen established an affiliate, Evogene Ltd. (TASE: EVGN.TA), to
utilize certain of the Company`s in-silico predictive discovery capabilities in
agricultural biotechnology. For additional information, please visit Compugen's
corporate Web site at www.cgen.com.

This press release may contain "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. These statements
include words such as "may", "expects", "anticipates", "believes", and
"intends", and describe opinions about future events. These forward-looking
statements involve known and unknown risks and uncertainties that may cause the
actual results, performance or achievements of Compugen to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Some of these risks are: changes in
relationships with collaborators; the impact of competitive products and
technological changes; risks relating to the development of new products; and
the ability to implement technological improvements. These and other factors are
identified and more fully explained under the heading "Risk Factors" in
Compugen's annual reports filed with the Securities and Exchange Commission.

Compugen Ltd.
Marjie Hadad
Global Media Liaison
Email: marjie@cgen.com
Tel: +972-54-536-5220

Copyright Business Wire 2009